Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Monograph from the Acute Leukemia Forum 1999 on Advances and Controversies in the Therapy of Acute Myelogenous Leukemia
  • Published:

Advances in the treatment of graft-versus-host disease

Abstract

Graft-versus-host disease (GVHD) is a complicated disease whose treatment requires an equally multifaceted approach. Recipient conditioning, donor T cell activation, and end stage effectors all may be potential targets for treatment. Many drugs used in the past are returning to the forefront for investigation. Some of the newer nucleoside analogs that are in various stages of development, such as fludarabine and pentostatin, are showing promising activity in GVHD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Hill GR, Cooke KR, Teshima T, Crawford JM, Keith JC Jr, Brinson YS, Bungard D, Ferrara JL . Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation J Clin Invest 1998 102: 115–123

    Article  CAS  Google Scholar 

  2. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R . Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 1998 91: 756–763

    CAS  PubMed  Google Scholar 

  3. Porter DL, Connors JM, Van Deerlin VMD, Duffy KM, McGarigle C, Saidman SL, Leonard DGB, Antin JH . Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies J Clin Oncol 1999 17: 1239–1243

    Article  Google Scholar 

  4. Schlegel PG, Aharoni R, Chen Y, Chen J, Teitelbaum D, Arnon R, Sela M, Chao NJ . A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine grant-versus-host disease in vivo Proc Natl Acad Sci USA 1996 93: 5061–5066

    Article  CAS  Google Scholar 

  5. Anasetti C, Hansen JA, Waldmann TA, Appelbaum FR, Davis J, Deeg HJ, Doney K, Martin PJ, Nash R, Storb R et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor Blood 1994 84: 1320–1327

    CAS  PubMed  Google Scholar 

  6. Or R, Weiss L, Teiman S, Polliack A . Fludarabine monophosphate reduces the incidence and severity of graft-versus-host disease in a murine model of bone marrow transplantation (letter) Blood 1997 90: 471

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vogelsang, G. Advances in the treatment of graft-versus-host disease. Leukemia 14, 509–510 (2000). https://doi.org/10.1038/sj.leu.2401687

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2401687

Keywords

This article is cited by

Search

Quick links